Targets › TXK
1 program from 1 company in 11 trials: 6 Phase 3, 5 Phase 2; Immunology, Metabolic and endocrine; next expected readout Dec 2026.
Non-receptor tyrosine kinase that plays a redundant role with ITK in regulation of the adaptive immune response. Regulates the development, function and differentiation of conventional T-cells and nonconventional NKT-cells. (UniProt, P42681)
Open in Phaseline: the race on TXK, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Pfizer | Ritlecitinib Tyrosine-protein kinase JAK3 inhibitor; TEC family kinase inhibitor | JAK3, ITK, BMX, TEC, TXK | Phase 3 | Severe Alopecia Areata; Vitiligo; Stable Nonsegmental Vitiligo; Alopecia Areata … | Dec 2026 |
Severe Alopecia Areata (2) Vitiligo (2) Alopecia Areata (2) Stable Nonsegmental Vitiligo (1) Hidradenitis Suppurativa (1) Chronic Spontaneous Urticaria (1) Keloid (1) Diabetes Mellitus, Type 1 (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.